SHANGHAI – Starting out with a bang, newly formed biopharma Cstone Pharmaceuticals Co. Ltd. has filed an investigative new drug application with the Jiangsu FDA for its recombinant anti-PD-L1 monoclonal antibody (WBP3155). The firm now awaits approval from the regulators before it can study the PD-L1 antibody in Chinese patients.
SHANGHAI – Hua Medicine Ltd. released the top-line results from the phase II trial of HMS5552, a fourth-generation glucokinase activator (GKA) used as a single drug to treat type 2 diabetes patients in China. The Shanghai-based biotech said the study shows statistically significant efficacy data, as well as an excellent tolerability and safety profile, with low risk of hypoglycemia or other side effects common in diabetes treatments.
SHANGHAI – Hua Medicine Ltd. released the top-line results from the phase II trial of HMS5552, a fourth-generation glucokinase activator (GKA) used as a single drug to treat type 2 diabetes patients in China. The Shanghai-based biotech said the study shows statistically significant efficacy data, as well as an excellent tolerability and safety profile, with low risk of hypoglycemia or other side effects common in diabetes treatments.
SHANGHAI – China's startup biotech scene has gained a new entrant: Transthera Biosciences Co. Ltd., of Nanjing, Jiangsu. Transthera has received $10 million, from a group of investors led by Morningside Ventures, to discover and develop new chemical entities (NCEs) for oncology, cardiovascular diseases and other indications.
SHANGHAI – China's startup biotech scene has gained a new entrant: Transthera Biosciences Co. Ltd., of Nanjing, Jiangsu. Transthera has received $10 million, from a group of investors led by Morningside Ventures, to discover and develop new chemical entities (NCEs) for oncology, cardiovascular diseases and other indications.
SHANGHAI – It’s not often that Chinese biopharmas are able to nab China rights for a promising late-stage oncology candidate in global trials. But that’s exactly what Shanghai-based Zai Lab Ltd. did when it obtained exclusive China rights for niraparib from Tesaro Inc., of Waltham, Mass. A PARP inhibitor, niraparib has shown promise in phase III ovarian cancer trials and is being evaluated in BRCA-mutant breast cancer and prostate cancer.
SHANGHAI – It's not often that Chinese biopharmas are able to nab China rights for a promising late-stage oncology candidate in global trials. But that's exactly what Shanghai-based Zai Labs Ltd. did when it obtained exclusive China rights for niraparib from Tesaro Inc.
SHANGHAI – Increasingly in China, innovation is meant to be a local game to create local champions, and foreign firms are lining up to find ways to be a part of the action, both big and small.
SHANGHAI – Increasingly in China, innovation is meant to be a local game to create local champions, and foreign firms are lining up to find ways to be a part of the action, both big and small.
SHANGHAI – Asia's contender in the CRISPR patent battle is now a step closer to seeing global IP claims validated. Toolgen Inc., of Seoul, South Korea, had two patent applications granted by the Korea Intellectual Property Office covering genome editing using the CRISPR platform. The two Korea patents cover fundamental claims for CRISPR/Cas-9-based genome editing in eukaryotic cells. Also included are claims covering modifications for improved specificity of CRISPR/Cas9 nucleases. The stakes are high for whoever succeeds in nailing down the patent for CRISPR – a new technology that many consider the most promising scientific and ethically troubling discovery of the past century.
